



CITURGIA BIOCHEMICALS LIMITED

Regd. Office: Office No. 427, A-Wing, 4th Floor Floor, Mainframe Premises C.S.L Royal Palms, Aareymilk Colony, Goregaon East, Mumbai-400065 Maharashtra, CIN: L24100MH1974PLC017773
Website: www.citurgiabiocchemicals.com; E-mail id: citurgia_bio@yahoo.com

To,

Date 14-02-2026

Listing Department,
BSE Limited
PJ, Towers, Dalal Street,
Mumbai-400001
Scrip Code: 506373
Scrip ID: CITURGIA

Sub: Submission of Unaudited Financial Results for Quarter ended 31st December, 2025

Dear Sir/Madam,

Please find enclosed herewith Unaudited Financial Results for the Quarter ended 31st December, 2025 along with Limited Review Report issued by the statutory auditor for the quarter ended 31st December, 2025 approved by the Board of directors in their meeting held on 14.02.2026.

The aforesaid meeting commenced at 03.00 P.M. and concluded at 05.00 P.M.

We request you to take the above information on record.

FOR CITURGIA BIOCHEMICALS LIMITED



KASHI NATH
WHOLE TIME DIRECTOR
DIN No. 02072952

Date : 14.02.2026

Place : Maharashtra

Amount in Lakhs

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST, DECEMBER 2025

| Particulars | | Quarter Ended | | | Period Ended | | Year Ended |
|-------------|---|---------------------------|-------------------------------------|---|--|---|--------------------------|
| | | 3 Months ended 31/12/2025 | Preceding 3 months ended 30/09/2025 | Corresponding 3 months ended 31/12/2024 | Year to Figure for current year ended 31.12.2025 | Year to Figure for previous year ended 31.12.2024 | Current Ended 31/03/2025 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| I. | Total Income from Operations | - | - | - | - | - | - |
| II. | Other Income | - | - | - | - | - | - |
| III. | Total Revenue (I+II) | - | - | - | - | - | - |
| IV. | Expenses | | | | | | |
| | a) Cost of Materials consumed | - | - | - | - | - | - |
| | b) Purchase of Stock-in-trade | - | - | - | - | - | - |
| | c) Changes in inventories of finished goods, WIP and stock in trade | - | - | - | - | - | - |
| | d) Employee benefits expenses | 4.40 | 4.40 | 4.40 | 11.80 | 11.80 | 16.90 |
| | e) Depreciation and amortisation expenses | 5.73 | 5.95 | 5.73 | 16.83 | 16.83 | 22.56 |
| | f) Other expenses | 18.71 | 0.85 | 0.30 | 18.97 | 5.41 | 2.84 |
| | Total Expenses | 28.84 | 11.20 | 10.43 | 47.60 | 34.04 | 42.31 |
| V | Profit/(Loss) before exceptional and extraordinary items and tax (III-V) | (28.84) | (11.20) | (10.43) | (47.60) | (34.04) | (42.31) |
| VI | Exceptional Items | - | - | - | - | - | - |
| VII | Profit/(Loss) before extraordinary items and tax (VI-VII) | (28.84) | (11.20) | (10.43) | (47.60) | (34.04) | (42.31) |
| VIII | Extraordinary items | - | - | - | - | - | - |
| IX | Profit/(Loss) before tax (VIII-IX) | (28.84) | (11.20) | (10.43) | (47.60) | (34.04) | (42.31) |
| X | Tax expenses | | | | | | |
| | a) Current Tax | - | - | - | - | - | - |
| | a) Income Tax Adjustment | - | - | - | - | - | - |
| | a) MAT Credit Entitlement | - | - | - | - | - | - |
| | b) Deferred Tax Liabilities / (Assets) | - | - | - | - | - | - |
| XI | Profit (Loss) for the period from continuing operations (IX-X) | (28.84) | (11.20) | (10.43) | (47.60) | (34.04) | (42.31) |
| XII | Profit/(loss) from discontinuing operations | - | - | - | - | - | - |
| XIII | Tax expense of discontinuing operations | - | - | - | - | - | - |
| XIV | Profit/(loss) from Discontinuing operations (after tax) (XII-XIII) | - | - | - | - | - | - |
| XV | Profit (Loss) for the period (XI + XIV) | (28.84) | (11.20) | (10.43) | (47.60) | (34.04) | (42.31) |
| XVI | Other Comprehensive Income | | | | | | |
| | A (i) Items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| | B (i) Items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - | - |

| | | | | | | | |
|-------|---|---------|---------|---------|---------|---------|---------|
| XVII | Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period) | (28.84) | (11.20) | (10.43) | (47.60) | (34.04) | (42.31) |
| XVIII | Earnings per equity share (for continuing operation): | | | | | | |
| | (1) Basic | 0.001 | 0.002 | 0.000 | 0.003 | 0.002 | 0.005 |
| | (2) Diluted | 0.001 | 0.002 | 0.000 | 0.003 | 0.002 | 0.005 |
| XIX | Earnings per equity share (for discontinued operation): | | | | | | |
| | (1) Basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| | (2) Diluted | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| XX | Earning Per Share (for discontinued & continuing operations) | | | | | | |
| | a) Basic | 0.001 | 0.002 | 0.000 | 0.003 | 0.002 | 0.005 |
| | b) Diluted | 0.001 | 0.002 | 0.000 | 0.003 | 0.002 | 0.005 |

NOTES :

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14th February, 2026.

2. The previous period figures have been rearranged / regrouped, wherever necessary to confirm to current period classifications.

3. The financial results are subject to the Limited Review Report issued by the statutory auditors of the company.

4. There are no investor complaints pending at the beginning and end of the quarter. The company did not receive any investor complaints during the quarter.

5. The Financial Results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules there under in terms of Regulation 33 of SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

FOR CITURGIA BIOCHEMICALS LIMITED



KASHI NATH
WHOLE TIME DIRECTOR
DIN No. 02072952

Date : 14.02.2026

Place : Maharashtra



G.P. KESHRI & ASSOCIATES

Chartered Accountants

Head Office: A-215/5, Chawla Complex, Vikas Marg, Shakarpur, New Delhi-110092 (Delhi)
Phone: +91 011 22546181, Mobile: +91 9818433797, +91 9911645535, +91 9654582358
Fax: +91 011 22546181, E-Mail: gopalkeshri@yahoo.com, vikashkes@gmail.com

LIMITED REVIEW REPORT

To,
**Board of Directors of
M/S Citurgia Biochemicals Limited**

We have reviewed the accompanying statement of Unaudited Financial Results of **M/S Citurgia Biochemicals Limited** (the "Company"), for the quarter and period ended 31st December 2025, being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Companies Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditors of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus accordingly, we do not express and audit opinion.

Based on our review conducted as above, nothing has come to our attention that caused us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued hereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and disclosed Requirements) Regulations, 2015 and SEBI circular dated 5th July 2016 including the manner in which it is to be disclosed, or that its contains any material misstatement.

**For M/s G.P.Keshri & Associates
Chartered Accountants**

**CA. Gopal Prasad Keshri
Partner
FRN: 017251N
M.NO: 098476**



**Place: New Delhi
Date: 14.02.2026
UDIN: 26098476IWJBKF6952**